Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IGC Pharma ( (IGC) ) has provided an announcement.
On December 30, 2025, IGC Pharma, Inc. announced that its Board of Directors approved a change in the company’s fiscal year-end from March 31 to December 31, effective December 31, 2025. To accommodate this shift, the company plans to file an annual transition report covering a nine-month period from April 1, 2025, through December 31, 2025, a move that will align its reporting calendar more closely with the standard calendar year and may simplify financial reporting and comparability for investors and other stakeholders.
The most recent analyst rating on (IGC) stock is a Hold with a $0.34 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.
Spark’s Take on IGC Stock
According to Spark, TipRanks’ AI Analyst, IGC is a Neutral.
IGC Pharma’s overall stock score reflects significant financial challenges, particularly in profitability and valuation. Technical analysis shows a bearish trend, while the recent asset sale is a positive strategic move. The company needs to address revenue growth and profitability to improve its financial position.
To see Spark’s full report on IGC stock, click here.
More about IGC Pharma
Average Trading Volume: 816,124
Technical Sentiment Signal: Strong Sell
Current Market Cap: $26.13M
For a thorough assessment of IGC stock, go to TipRanks’ Stock Analysis page.